Table 4.

The Risk Ratio of 3 Glycoprotein IIb-IIIa Inhibitors.^a

	No.	ICH (95% CI)	No.	SICH (95% CI)	No.	Mortality (95% CI)
Analysis for only randomized control trials
Total	6	1.05 (0.82-1.34)	6	1.78 (1.04-3.04)	7	0.92 (0.66-1.28)
Abciximab	2	1.87 (0.64-5.48)	2	4.26 (1.89-9.59)	3	0.93 (0.60-1.45)
Eptifibatide	2	0.59 (0.33-1.08)	2	0.17 (0.04-0.69)	2	1.47 (0.69-3.09)
Tirofiban	2	1.13 (0.77-1.63)	2	0.50 (0.092.71)	2	0.58 (0.28-1.20)
Analysis for all type studies
Total	15	1.21 (0.90-1.62)	16	1.16 (0.92-1.46)	14	0.76 (0.65-0.89)
Abciximab	3	1.27 (0.89-1.81)	4	1.88 (1.17-3.00)	5	0.70 (0.54-0.90)
Eptifibatide	2	0.59 (0.32-1.08)	2	0.17 (0.04-0.69)	2	1.47 (0.69-3.09)
Tirofiban	10	1.27 (0.84-1.93)	10	1.04 (0.78-1.38)	7	0.75 (0.61-0.93)

Abbreviations: ICH, intracerebral hemorrhage; SICH, symptomatic intracranial hemorrhage.

^a No. means number of studies analyzed.

The boldface values means the risk ratio is significant.